canertinib dihydrochloride has been researched along with leflunomide in 1 studies
| Studies (canertinib dihydrochloride) | Trials (canertinib dihydrochloride) | Recent Studies (post-2010) (canertinib dihydrochloride) | Studies (leflunomide) | Trials (leflunomide) | Recent Studies (post-2010) (leflunomide) |
|---|---|---|---|---|---|
| 31 | 13 | 6 | 1,725 | 173 | 659 |
| Protein | Taxonomy | canertinib dihydrochloride (IC50) | leflunomide (IC50) |
|---|---|---|---|
| Dihydroorotate dehydrogenase (quinone), mitochondrial | Mus musculus (house mouse) | 0.03 | |
| Cytochrome P450 1A2 | Homo sapiens (human) | 0.5 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 4.63 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 4.63 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 2.884 | |
| Dihydroorotate dehydrogenase (quinone), mitochondrial | Homo sapiens (human) | 5.4 | |
| Dihydroorotate dehydrogenase (quinone), mitochondrial | Rattus norvegicus (Norway rat) | 0.009 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aggarwal, R; Belsey, JD; Brack, K; Bulle, A; Chen, Z; Fluck, D; John, I; Kodre, A; Kralj-Hans, I; Lamorgese, A; Li, HL; Li, K; Li, L; Li, S; Marczin, N; McGee, M; Omar, F; Ranasinghe, K; Seshasai, SRK; Sharma, P; Sharma, S; Wesek, A | 1 |
1 trial(s) available for canertinib dihydrochloride and leflunomide
| Article | Year |
|---|---|
Leflunomide treatment for patients hospitalised with COVID-19: DEFEAT-COVID randomised controlled trial.
Topics: Adult; Aged; COVID-19; Female; Humans; Leflunomide; Male; Middle Aged; Oxygen; Prospective Studies; SARS-CoV-2; Treatment Outcome | 2023 |